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High specificity is an important requirement for an analytical system aimed at identifying a specific 
molecular target. Traditionally, antibodies, haptens and some other molecules are used for this 
purpose. Recently, aptamers were proposed as biospecific elements. Aptamers are short single-
stranded oligonucleotides with a unique spatial structure that enables them to recognize target 
molecules and bind to them. Aptamers are obtained from synthetic random DNA(RNA)-libraries, 
a pool of oligonucleotides of the same length with different base sequences (1014-1015 variants), by 
selecting the oligonucleotides that are capable of specific binding to a given target. Aptamers are 
stable molecules with high affinity and specificity; they can be developed for any target, including 
toxic and nonimmunogenic ones; and they can be easily synthesized chemically. Due to these useful 
qualities, aptamers are often considered to be an alternative to antibodies. This paper describes 
the use of aptamer sensors and a highly sensitive bioluminescent reporter, the Ca2+-regulated 
photoprotein obelin, for the detection of diagnostically important targets in the blood of patients. 
Additionally, obelin was successfully applied as a reporter in the process of obtaining aptamers. A 
proposed bioluminescent solid-phase assay enables the enrichment of the oligonucleotide library with 
target-specific oligonucleotides to be monitored rapidly, the affinity of individual aptamers and their 
shortened variants to be evaluated and the relative position of the aptamers on the target molecule to 
be determined. The results of the studies reviewed in this paper open promising avenues for developing 
analytical systems that include highly specific aptamer sensing, as well as highly sensitive detection 
based on bioluminescent reporter proteins.
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Биолюминесцентный молекулярный микроанализ  
на основе аптамерной сенсорики
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Н.С. Гончароваа,б, В.В. Красицкаяа
аИнститут биофизики СО РАН 
ФИЦ «Красноярский научный центр СО РАН» 
Россия, 660036, Красноярск, Академгородок, 50/50 
бСибирский федеральный университет 
Россия, 660041, Красноярск, пр. Свободный, 79
Важнейшим качеством аналитической системы, направленной на выявление определенной 
молекулярной мишени, считается высокая специфичность. Традиционно для этого используют 
антитела, гаптены и пр. Сравнительно недавно в качестве биоспецифических элементов 
были предложены аптамеры – короткие одноцепочечные олигонуклеотиды, обладающие 
уникальной пространственной структурой, благодаря чему способные «распознавать» 
и специфическим образом связываться с молекулами-мишенями. Аптамеры получают из 
синтетических рандомных ДНК(РНК)-библиотек, совокупности олигонуклеотидов одинаковой 
длины с разной последовательностью оснований (1014-1015 вариантов), путем отбора тех, что 
способны специфическим образом связываться с данной мишенью. Аптамеры стабильны, 
обладают высокой аффинностью и специфичностью, их можно получать к любым мишеням, 
в том числе неиммуногенным и токсичным, их легко синтезируют химически. Благодаря 
этим преимуществам аптамеры часто рассматривают как альтернативу антителам. В 
данной работе описаны случаи применения аптамерной сенсорики и высокочувствительного 
биолюминесцентного репортера – Са2+-регулируемого фотопротеина обелина для 
выявления диагностически важных мишеней в крови пациентов. Этот же репортер 
предложено использовать при получении новых аптамеров. Разработанный оригинальный 
биолюминесцентный твердофазный анализ позволяет быстро отслеживать процесс 
обогащения синтетических библиотек специфичными к данной мишени олигонуклеотидами, 
оценивать аффинность полученных индивидуальных аптамеров и их укороченных вариантов, а 
также взаимное расположение аптамеров на молекуле-мишени. Результаты рассмотренных 
в работе исследований показывают перспективность разработки аналитических систем, 
включающих, с одной стороны, высокоспецифичную аптамерную сенсорику, а с другой – 
высокочувствительную детекцию на основе биолюминесцентных репортерных белков.
Ключевые слова: аптамеры, Са2+-регулируемый фотопротеин обелин, биолюминесцентный 
микроанализ.
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Introduction
The process of binding analysis includes 
recognition of the target with the formation of 
a specific complex, the appearance of which 
is detected by the various reporters (Fig. 1). 
Some examples of reporters are radioisotopes, 
fluorophore molecules, and enzymes that generate 
visually detectable (or measurable) products (e.g., 
color and light).
In this study, we discuss a bioluminescent 
reporter, that is, an enzyme generating a quantum 
of visible light as one of the products of the 
reaction it catalyzes.
The common name for such enzymes 
is luciferase, and their substrates are called 
luciferins. At present, a large variety of luciferases 
have been characterized, each of which catalyzes 
the oxidation of the corresponding luciferin. A 
specific kind of luciferases are the Ca2+-regulated 
photoproteins of marine coelenterates, particularly 
obelin of the hydroid Obelia longissima. Obelin 
is a stable noncovalent complex of a single-
chain polypeptide (apo-obelin) and preoxidized 
luciferin, 2-hydroperoxycoelenterazine. Obelin 
bioluminescence is triggered by Ca2+, which is 
why it is referred to as a ‘Ca2+-regulated’ protein. 
Obelin has been successfully used as a reporter 
in bioluminescent binding assays for determining 
different diagnostically important targets, 
including hormones, oncomarkers, infection 
agents, and single nucleic polymorphisms (Frank, 
2010). The assay provides highly sensitive and 
repeatable target detection with fast and simple 
signal reading, supporting that obelin is a reporter 
of choice.
To provide specificity to the binding assay, 
the label must contain a recognition element able 
to bind to the target with high affinity (Fig. 1). 
Usually, this element is an antibody or a hapten 
binding protein (e.g., in the case of streptavidin-
biotin interaction). Relatively new biospecific 
molecules are aptamers, single-stranded DNA 
or RNA oligonucleotides (20-80 bases long) 
that fold into certain structures, exhibiting high 
specificity when binding to the target of interest. 
In the assay, aptamers function in a similar way 
to antibodies but successfully compete with 
them because aptamers are easily synthesized 
chemically (no animals needed) and can be 
selected for almost any target, including those 
that have low molecular weight and are toxic 
or nonimmunogenic. Due to these advantages, 
aptamers are becoming increasingly popular as 
biospecific elements in a number of biomedical 
analytical systems (Zhou et al., 2014). There 
are many methods (e.g., ultrafiltration, gel 
and capillary electrophoresis, HPLC, circular 
dichroism, and surface plasmon resonance) used 
to develop and characterize novel aptamers, 
which is usually a complicated and time-
consuming process. In this study, we consider 
a novel, rapid and simple method for aptamer 
development based on the obelin bioluminescent 
signal. Additionally, the paper describes several 
Fig. 1. General scheme for binding analysis
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examples showing successful application of the 
developed bioluminescent binding microassay 
for examining clinical samples.
Bioluminescent solid-phase assay  
for aptamer development
Usually, aptamers bound to the target of 
interest are obtained from large synthetic random 
libraries (1014–1015 sequences) through the 
systematic evolution of ligands by exponential 
enrichment (SELEX) procedure (Fig. 2). The 
process of aptamer selection includes several 
rounds of the repeating steps: incubation 
with the target (unbound material discarded), 
dissociation of bound oligonucleotides and their 
amplification.
A novel approach to monitor the course of 
selection based on the Ca2+-regulated photoprotein 
obelin was proposed by Krasitskaya et al. 
(Institute of Biophysics, SB RAS). The general 
scheme of the analysis is presented in Fig. 3a. 
With the approach applied, DNA aptamers to the 
cardiac marker troponin I and RNA aptamers to 
hemoglobins (general and glycated) (Davydova 
et al., 2019) and obelin (Krasitskaya et al., 2018) 
were developed within a short period of time and 
at relatively low cost. Fig. 3b-d shows the results 
on the library enrichment during the selection 
of the affine aptamers. Evaluation of individual 
aptamers’ affinity by the bioluminescent solid-
phase assay is shown in Fig. 3e-g. Using the assay 
data, the saturation curves were obtained, and the 
dissociation constants of aptamer-corresponding 
target complexes were calculated.
The assay requires 1.5-2 h; incubations 
are the longest stages of this analysis, while 
the measurement of the bioluminescent signal 
requires 3 to 5 seconds. The high sensitivity of 
obelin-based labels enables aptamer affinity 
within a low concentration range to be studied.
Bioluminescent DNA aptamer-based  
solid-phase microassay for lung tumor  
element detection in plasma  
(Bashmakova et al., 2019, 2019a)
According to statistical data, lung cancer 
is a leading cause of cancer-related deaths 
worldwide. Despite the variety of screening 
methods used, many patients with this type of 
cancer begin treatment at stages 3 or 4, when 
the tumor is no longer responsive to current 
therapies. Therefore, early clinical screening 
for premetastatic malignant tumors is highly 
important. A promising tool for better lung 
cancer screening and monitoring is evaluation 
and enumeration of circulating tumor elements 
(e.g., cells, cell debris, microemboli) in blood. 
Recently, a group of 10 DNA aptamers specific to 
Fig. 2. General scheme for aptamer selection and study
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lung adenocarcinoma postoperative tissues was 
selected. Fluorescently labeled aptamers from 
this group, LС-17 and LC-18, were successfully 
applied to detect blood circulating tumor cells 
in patients with lung adenocarcinoma using 
confocal fluorescence microscopy (Zamay 
et al., 2015) and to histologically examine 
lung adenocarcinoma (Zamay et al., 2017). 
These 80-base aptamers show high affinity 
for postoperative lung tissue (kd=14 nM and 
38 nM, respectively) (Zamay et al., 2015) and 
are specific to different ligands. This property 
enabled us to propose a sandwich-type solid-
phase analysis of lung tumor elements in plasma 
using these aptamers as biospecific recognition 
elements and the photoprotein obelin as a signal 
element (Fig. 4a). This analysis is notably simple 
and fast compared to confocal fluorescence 
microscopy.
The surface of magnetic microspherical 
particles activated by aptamer LC-17 was used 
to capture and accumulate the targets. Aptamer 
LC-18 forms a sandwich-type complex, which 
is detected using obelin bioluminescence. For 
complex connections, the same oligonucleotide 
complementary to the 5’ terminus of both 
aptamers labeled with biotin or obelin molecules 
was used. In this study, we note that aptamers 
share technological 20-base terminal fragments, 
whereas their central 40-base part is variable 
and usually defines aptamer affinity. Thus, the 
scheme includes two universal connectors: 
biotinylated oligonucleotide to form the 
analytical complex on the surface and the same 
oligonucleotide conjugated with obelin to detect 
the complex through a bioluminescent signal. 
This approach enables the use of any aptamer to 
any target if they share the same technological 
Fig. 3. Bioluminescent assay for aptamer development. Scheme of the assay (a); analyses of library enrichment 
(b-d) and affinity of individual aptamers (e-g) to the targets: cardiac troponin I (cTnI), hemoglobin (Hb), 
hexahistidine-obelin (His-Obelin). Stavi – streptavidin, Label – conjugate obelin-biospecific molecule
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20-base terminal fragments (Bashmakova et al., 
2019a).
Control experiments on model samples 
prepared from postoperative cancer and healthy 
lung tissues prove the approach to be applicable. 
Evidently, the bioluminescent signal decreases 
in diluted cancer samples and remains at a 
constantly low level in healthy lung tissue samples 
(Fig. 4b).
Next, 50 clinical plasma samples provided 
by the Krasnoyarsk Regional Clinical Oncology 
Center, named after A.I. Kryzhanovsky, were 
tested. The samples were collected prior to tumor 
resection surgery, and lung cancer diagnosis 
was histologically confirmed after surgery. The 
control group contained 48 samples collected 
from healthy donors in terms of lung cancer. 
The results of the bioluminescent aptamer-based 
assay in plasma samples from patient and control 
groups are shown in Fig. 4c. Elevated signal 
levels in lung cancer patients were statistically 
significant (p < 0.001). The chosen threshold 
value as the clinical decision limit offers an assay 
sensitivity of 91.5% and a specificity of 75%. In 
this study, there were 10 cases at the first stage of 
cancer (the tumor is found in the lung but has not 
spread outside of it), 12 cases at the second stage, 
18 at the third stage, and 7 cases at the fourth 
stage (cancer has spread to the lung, into the area 
around the lung or to distant organs). The signals 
from samples at different stages were compared 
using the Kruskal-Wallis test. No significant 
differences between the groups (p > 0.05) were 
shown. Satisfactory results were obtained at the 
Fig. 4. Bioluminescent DNA aptamer-based solid-phase microassay for lung tumor element detection in plasma 
(a). Proof of the assay principle using two clinical (gray columns) and control plasma samples (b). Plasma sampling 
of patients and controls (c)
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early stage of detection: the assay was able to 
reveal 8 out of 10 cases at the first stage of cancer 
and 11 out of 12 cases at the second stage. For the 
late cancer stages, the assay detected 17 out of 18 
cases at the third stage of cancer and all the cases 
at the fourth stage.
Thus, the study demonstrates the potential 
of the bioluminescent assay involving aptamers 
as sensory elements for lung cancer detection and 
monitoring.
Assay of anti-MBP autoantibodies  
associated with multiple sclerosis  
(Krasitskaya et al., 2019)
Multiple sclerosis (MS) is a chronic 
autoimmune-mediated disease of the central 
nervous system, usually associated with varying 
degrees of progressive disability. The initial 
and precise etiology of this disease has not 
been determined and is probably multifactorial. 
In addition, the course of the disease is highly 
variable and difficult to predict. Early diagnosis 
and timely treatment may decelerate disease 
progression and improve patients’ lives. Today, 
MS diagnosis requires several diagnostic tests, 
including magnetic resonance imaging (MRI) and 
cerebrospinal fluid analysis, which are expensive, 
time-consuming and fraught with adverse effects. 
Pathogenic autoantibodies to myelin basic protein 
(anti-MBP) were first reported in 1980 (Panitch 
et al., 1980). It was ascertained that anti-MBP 
autoantibodies found in the sera of MS patients 
possess proteolytic activity and thus contribute 
to demyelination and disease pathogenesis in 
MS patients. These autoantibodies are believed 
to be good candidate biomarkers for diagnosing 
MS and monitoring disease activity (e.g., see the 
review Comabella, Montalban, 2014). The most 
important analytical problem facing this analysis 
is a low content (not more than 1%) of anti-MBP 
autoantibodies compared to the total antibodies 
in sera.
Several modified RNA aptamers with high 
affinity (KD values of approximately 3-7 nM) 
to anti-MBP autoantibodies have been recently 
obtained (Krasitskaya et al., 2019; Vorobjeva et al., 
2014). To provide RNA resistance to ribonuclease 
cleavage, all pyrimidines in their sequences were 
replaced with 2’-fluoro analogues.
Based on these aptamers and obelin, a 
bioluminescent solid-phase sandwich assay 
for the pathogenic anti-MBP antibodies was 
developed (Fig. 5). One aptamer (Apt 12-2b, 
Fig. 5a) was adsorbed on the microwell surface 
and “worked” on the target capturing, whereas 
the other aptamer (Apt 2-9c) preconjugated 
with obelin was applied as a specific 
bioluminescent probe to reveal the complex. 
The assay was first tested on model samples of 
hIgG at a constant concentration (1.5 mg/mL) 
spiked with anti-MBP autoantibodies (Fig. 5b). 
The analysis revealed a relative content of 
pathogenic autoantibodies up to 0.15% of total 
hIgG. Using the assay conditions determined 
in model experiments, samples from MS-
diagnosed patients (91) and non-MS donors 
(81) were analyzed. A statistical analysis of the 
results showed a 63.7% sensitivity and a 94.2% 
specificity of the assay developed (Fig. 5c).
The calculated AUC value of 0.87 
demonstrates a statistically significant (p < 0.001) 
difference between the two groups under study. 
The negative predictive value (NPV) of 96.3% 
represents the number of patients with negative 
test results who do not have the disease. The 
positive predictive value (PPV) of 52% represents 
the number of patients with positive test results 
who have the disease. Although the majority 
of patients (82.4%) were of relapsing-remitting 
subtype, this group was heterogeneous regarding 
such factors as the history of the disease and the 
therapy used. Therefore, further investigations are 
needed to consider the relationship between anti-
MBP antibody levels and such factors as disease 
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stage and therapy. The analysis developed in this 
study can be a useful tool for clarifying many 
issues related to the emergence, development and 
treatment of this disease.
Conclusion
Modern analytical technologies based on 
aptamers, that is, biospecific molecules that 
can be obtained by chemical synthesis, easily 
modified and stored for a long time, have opened 
considerable avenues for researchers to create 
methods for identifying novel diagnostically 
important targets. Using bioluminescent 
reporters ensures a high-sensitivity analysis. 
Taken together, these factors can promote early 
diagnosis of the disease, which significantly 
affects treatment success. The results of the 
preliminary experiments described in this report 
demonstrate the potential of developing new 
analytical approaches involving aptamer sensors 
and bioluminescent reporters.
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Fig. 5. Bioluminescent solid-phase assay of anti-MBP autoantibodies associated with multiple sclerosis (a). Assay 
of artificial sera (b). MS-patients’ and controls’ sera sampling (c)
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